CM Management’s Travere Therapeutics TVTX Stock Holding History

CM Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-80,000	Closed	-$1.94M	–	95
2021 Q3	$1.94M	Buy	80,000 +20,000	+33%	+$367K	1.45%	19
2021 Q2	$875K	Buy	60,000 +28,000	+88%	+$552K	0.63%	56
2021 Q1	$799K	Hold	32,000	–	–	0.59%	67
2020 Q4	$872K	Buy	+32,000	New	+$747K	0.81%	42

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CM Management's TVTX Position: Q4 2021 in Review

CM Management sold out of Travere Therapeutics (TVTX) in Q4 2021, closing a stake of 80,000 shares — an estimated $1.94M sold.

CM Management first reported a position in TVTX in Q4 2020 and held it in 4 quarters. The position peaked at $1.94M in Q3 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q4 2021.

CM Management reported no remaining Travere Therapeutics position as of Q4 2021 after selling out during the quarter.
CM Management sold 80,000 Travere Therapeutics shares in Q4 2021, an estimated $1.94M.
CM Management first reported a position in Travere Therapeutics in Q4 2020 and held it in 4 quarters.
CM Management's Travere Therapeutics position peaked at $1.94M in Q3 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2021.

Based on CM Management's 13F filing for Q4 2021, filed 2 Feb 2022.